Acupuncture for Overactive Bladder in Adults
NCT05158361 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110
Last updated 2024-03-04
Summary
The purpose of this study is to assess the effectiveness and safety of acupuncture for treating overactive bladder in adults.
Conditions
Interventions
- OTHER
-
Acupuncture
Participants will receive acupuncture, three times per week for eight weeks. The selected acupoints include bilateral BL33, BL35, SP6, and ST36. All acupoints areas have been sterilized before acupuncture. For BL33, a needle (Ф0.40×100mm) will be inserted with an angle of 60° in an inferomedial direction at a depth of 90-100mm. For BL35, the same needle will be inserted with a direction to the ischial rectal fossa at a depth of 60-70 mm deep. For SP6 and ST36, needles (Ф0.30×50mm) will be directly inserted at a depth of 25-30 mm deep. After the needles are inserted, a portable electro-acupuncture machine will be connected to the handles of needles located in BL33 and BL35 to provide the electrical stimulation for 30 minutes with a disperse-dense wave (4/20Hz). All current intensities will be as high as can be tolerated.
- OTHER
-
Sham acupuncture
The sham acupoints will be located at 20 mm outward to BL33, BL35, SP6, and ST36, and the needless will be inserted with a depth of 2 mm. The BL33 and BL35 will not receive any electrical stimulation, though the handles of needles will be connected to the same machine as the acupuncture group, and the parameter setting and course are also the same.
Sponsors & Collaborators
-
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
lead OTHER
Principal Investigators
-
Ran Pang, MD · Guang'anmen hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-08
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- China
Study Locations
More Related Trials
-
Overactive Bladder Syndrome
NCT05151081 ·Status: COMPLETED
-
Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial
NCT05157295 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Transcutaneous Versus Percutaneous Posterior Tibial Nerve Stimulation in the Overactive Bladder.
NCT04483817 ·Status: UNKNOWN ·Phase: NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
NCT04305743 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
NCT06408051 ·Status: COMPLETED
-
OnabotulinumtoxinA Bladder Injection Study
NCT03523091 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 ·Status: COMPLETED ·Phase: PHASE3
-
Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women
NCT03807024 ·Status: COMPLETED
-
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
NCT04020510 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
NCT01210859 ·Status: WITHDRAWN
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
NCT01029015 ·Status: COMPLETED
-
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder
NCT06250543 ·Status: COMPLETED ·Phase: PHASE4
-
InSite for Over Active Bladder
NCT00547378 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
NCT00742833 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
NCT01003405 ·Status: WITHDRAWN ·Phase: PHASE3
-
Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
NCT03758235 ·Status: UNKNOWN ·Phase: PHASE3
-
Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
NCT06953271 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
NCT02820844 ·Status: COMPLETED ·Phase: PHASE3
-
Overactive Bladder Telemedicine Non-inferiority Trial
NCT05117918 ·Status: COMPLETED ·Phase: NA
-
Evaluating a Digital Intervention for Overactive Bladder
NCT05170100 ·Status: COMPLETED ·Phase: NA
-
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 ·Status: COMPLETED ·Phase: PHASE3
-
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
NCT01004315 ·Status: COMPLETED ·Phase: PHASE3
-
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
NCT01512004 ·Status: COMPLETED ·Phase: PHASE3